Hypotension and Shock Clinical Trial
Official title:
A Randomized Controlled Trial of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation
Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information.
Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Data from a recent randomized controlled study showed the improve long term survival among shock patients whose resuscitated with colloid solution. There were evidence about the increase incidence of acute kidney injury among critically ill patients who received hydroxyethyl starch, a previously worldwide used colloid solution. For septic shock, the leading cause of shock in current situation, resuscitation with albumin may associated with better outcome, while increasing mortality had been reported among the patient who received hydroxyethyl starch. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06121115 -
Norepinephrine Administration Through a Midline Catheter in an Intermediate Care Unit
|
||
Terminated |
NCT04538079 -
Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates
|
||
Completed |
NCT03701646 -
ClearSight Validation in Pediatrics
|
||
Completed |
NCT02070276 -
Predict Fluid Responsiveness in Spinal Anesthesia
|
N/A | |
Completed |
NCT04891380 -
BCG Biosensor and Non- and Invasive Monitoring During Emergency Medicine Cases, a Prospective Feasibility Study
|
N/A | |
Completed |
NCT03927066 -
Physiological Validation of Current Machine Learning Models for Hemodynamic Instability in Humans
|
N/A | |
Recruiting |
NCT04760977 -
Prehospital Management of Hypotensive Trauma in HEMS
|
||
Completed |
NCT03582501 -
Measurement of Hemodynamic Responses to Lower Body Negative Pressure
|
N/A | |
Terminated |
NCT03407287 -
Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status
|
||
Active, not recruiting |
NCT04688450 -
BP Management System User Acceptance Testing
|
N/A | |
Terminated |
NCT03214809 -
The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams
|
N/A | |
Not yet recruiting |
NCT03671070 -
Role of Low Dose Epinephrine Boluses In Acute Hypotension
|
N/A | |
Completed |
NCT04497155 -
Prehospital Norepinephrine and Early Mortality in Traumatic Shock
|
||
Completed |
NCT04269382 -
Accuracy of Non-Invasive Blood Pressure Measurements at the Arm, Calf , and Finger
|
N/A | |
Recruiting |
NCT05931601 -
Early Initiated Vasopressor Therapy in the Emergency Department
|
Phase 3 | |
Recruiting |
NCT05355974 -
Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure
|
Phase 3 | |
Completed |
NCT04529005 -
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
|
Phase 4 |